Report Description Table of Contents Prediabetes Market: How Are Early Screening and Structured Prevention Shaping Demand? – (Updated On: 11th-Nov-2026) According to Strategic Market Research, The Global Prediabetes Market was independently estimated at USD 313.8 million in 2025 and is projected to reach USD 504.0 million by 2032, expanding at a CAGR of 7.0% during 2026–2032. The projected USD 190.2 million increase in market value reflects growing demand for early blood glucose screening, HbA1c testing, diabetes risk assessment, preventive medication, structured lifestyle intervention, and follow-up monitoring. The market covers diagnostic testing, preventive healthcare services, lifestyle modification programs, digital diabetes prevention platforms, and selected pharmacological interventions for individuals with elevated blood sugar who have not developed Type 2 diabetes. The large prediabetes population is creating demand for early diagnosis and preventive healthcare services. According to the International Diabetes Federation (IDF), approximately 634.8 million adults aged 20–79 worldwide had impaired glucose tolerance (IGT) in 2024, representing 12.0% of the global adult population. This figure is projected to reach 846.5 million by 2050. In the United States, the CDC estimated that 115.2 million adults had prediabetes in 2023. This growing patient population creates opportunities for blood glucose testing, early diagnosis, clinical assessment, and preventive interventions to reduce progression to Type 2 diabetes. Low awareness of prediabetes is increasing the need for early blood sugar testing. According to the CDC, only 19.8% of U.S. adults with prediabetes knew they had the condition during 2021–2023. This means approximately 8 in 10 were unaware. Another CDC study involving 1.34 million adults found that only 33.4% received an HbA1c or fasting blood glucose test over three years. When other glucose tests were included, testing reached 74.3%. These findings highlight opportunities for diagnostic laboratories and healthcare providers to expand early screening and identify more at-risk individuals. Prediabetes does not always lead to Type 2 diabetes, making early monitoring important. A pooled analysis of 19 studies involving 76,092 participants found that 12.5% of people with prediabetes developed Type 2 diabetes within 10 years, while 36.1% returned to normal blood sugar levels. This means that some people can improve their condition through timely care and lifestyle changes, while others remain at risk of diabetes. These findings support demand for regular HbA1c tests, fasting blood glucose testing, and follow-up consultations to track blood sugar changes and identify patients who need preventive care. Source: PubMed – Prediabetes Progression Study. Competition in the prediabetes market includes companies supplying diagnostic tests and structured prevention programs. Labcorp and Quest Diagnostics offer HbA1c and blood glucose testing used to identify elevated glucose levels. Omada Health provides a digital diabetes prevention program combining health coaching, behavior-change support, and connected tools, while Lark Health and Noom offer digital lifestyle programs focused on nutrition, physical activity, and weight management. Metformin is also used for selected high-risk patients, although it is not FDA-approved specifically for prediabetes prevention. Through 2032, the Prediabetes Market will be supported by the large population requiring early diagnosis, low awareness of elevated blood glucose, and increasing adoption of preventive healthcare services. Diagnostic testing will remain an important entry point for identifying eligible patients, while lifestyle modification, selected preventive medication, and structured diabetes prevention programs will support continued service demand. Commercial opportunities will depend on screening accessibility, repeat diagnostic testing, patient enrollment and retention, healthcare reimbursement, and the ability of providers to demonstrate measurable reductions in progression to Type 2 diabetes. Which Prediabetes Market Subsegments Are Leading Across Diagnosis, Treatment, and Regional Adoption? By Disease Type: Fasting and Post-Meal Glucose Abnormalities Shape Risk Assessment Leading Subsegment: Impaired Fasting Glucose (IFG) Impaired Fasting Glucose (IFG) accounted for the largest share of the Prediabetes Market in 2025, representing 40% and a market value of USD 125.52 million. IFG is a key diagnostic marker of prediabetes, an intermediate condition in which fasting blood glucose exceeds the normal range but remains below the diagnostic threshold for type 2 diabetes. Wider use of routine blood glucose screening supports earlier clinical identification. IFG is projected to expand at a CAGR of 6.44% from 2026 to 2032. Fastest-Growing Subsegment: Combined IFG and IGT Combined Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) account for 26% of the Prediabetes Market, equivalent to USD 81.59 million in 2025. The combined condition represents a high-risk prediabetes phenotype, as abnormalities in fasting and post-meal glucose regulation can indicate greater progression risk for type 2 diabetes than either condition alone. Its market share is projected to record the fastest CAGR of 8.04% during 2026–2032, highlighting the clinical importance of identifying and monitoring people with overlapping glucose abnormalities. By Diagnosis: HbA1c Testing Connects Screening with Follow-Up Care Leading and Fastest-Growing Subsegment: HbA1c Testing HbA1c testing represents 42% of the Prediabetes Market, valued at USD 131.80 million in 2025, and is projected to grow at a CAGR of 8.00% during 2026–2032. The test measures the proportion of glucose attached to hemoglobin in red blood cells, reflecting average blood glucose levels over the previous two to three months. By identifying persistently elevated glucose before diabetes develops, HbA1c testing supports prediabetes screening, risk assessment, and follow-up monitoring, helping clinicians guide lifestyle changes and timely clinical intervention. By Treatment: Lifestyle Programs and Selected Medicines Support Prevention Leading Subsegment: Lifestyle Modification Lifestyle modification remains the primary, evidence-based approach in the Prediabetes Market, accounting for 42% of the market, or USD 131.80 million in 2025, and is projected to expand at a CAGR of 6.61% during 2026–2032. Structured nutrition plans, regular physical activity, weight management, and behavioral support help people with prediabetes improve glucose regulation, prevent progression to type 2 diabetes and, in some cases, restore glucose levels to the normal range. Its role supports adoption across primary care and prevention programs. Fastest-Growing Subsegment: Pharmacological Management Pharmacological management accounted for 30% of the Prediabetes Market in 2025, equivalent to USD 94.14 million, and is projected to expand at a CAGR of 7.81% during 2026–2032. Medications can complement lifestyle interventions in individuals at high risk of developing type 2 diabetes, particularly when dietary modifications, weight management, and regular physical activity alone are insufficient to reduce progression risk. Earlier identification of high-risk individuals and clinical assessment may support the appropriate use of preventive pharmacological therapies under medical supervision. By Drug Class: Metformin and Incretin Therapies Address Different Patient Needs Leading Subsegment: Biguanides (Metformin) Biguanides, primarily metformin, account for 55% of the Prediabetes Market’s pharmacological management category, equivalent to USD 51.78 million in 2025, and are projected to grow at a CAGR of 5.92% from 2026 to 2032. Metformin is prescribed to selected individuals with prediabetes who face a higher risk of developing Type 2 diabetes, particularly those with additional risk factors. By improving insulin sensitivity and reducing hepatic glucose production, treatment can delay or prevent progression to clinical Type 2 diabetes alongside lifestyle interventions. Fastest-Growing Subsegment: GLP-1 Receptor Agonists Glucagon-like peptide-1 receptor agonists (GLP-1RAs) accounted for 25% of the drug-class breakdown in 2025, equivalent to USD 23.54 million, and are projected to register the fastest CAGR of 11.92% during 2026–2032. Their therapeutic relevance in prediabetes is increasing, particularly among individuals with overweight or obesity. GLP-1RAs and dual GLP-1/GIP receptor agonists such as tirzepatide support weight reduction and improved glycemic control, potentially reducing the risk of progression to type 2 diabetes. Clinical studies continue to assess their benefits. By Monitoring: Periodic HbA1c Checks and CGM Support Preventive Follow-Up Leading Subsegment: HbA1c Monitoring HbA1c monitoring accounts for 50% of the Prediabetes Market, equivalent to USD 156.90 million in 2025, and is projected to grow at a CAGR of 6.73% from 2026 to 2032. The HbA1c test measures the percentage of hemoglobin in red blood cells that has glucose attached, reflecting average blood glucose levels over roughly the previous two to three months. Its role in identifying elevated glucose and tracking progression toward type 2 diabetes supports its use in screening and follow-up for prediabetes. Fastest-Growing Subsegment: Continuous Glucose Monitoring (CGM) Systems Continuous Glucose Monitoring (CGM) systems are gaining relevance in the Prediabetes Market by helping individuals monitor glucose fluctuations, identify dietary and lifestyle-related patterns, and track progress during preventive interventions. Traditionally associated with established diabetes management, CGM technology is increasingly being explored for early metabolic risk identification and personalized diabetes prevention. In 2025, CGM systems accounted for 12% of the Prediabetes Market, valued at USD 37.66 million, and are projected to grow at an 11.43% CAGR during 2026–2032, globally. By End User: Specialist Clinics Coordinate Early Diagnosis and Metabolic Care Leading and Fastest-Growing Subsegment: Diabetes and Endocrinology Clinics Diabetes and endocrinology clinics play a specialized role in prediabetes identification, risk assessment, and long-term metabolic care. Their expertise in interpreting blood glucose and HbA1c results supports early diagnosis, personalized lifestyle guidance, and regular monitoring to reduce progression to type 2 diabetes. Clinics accounted for 38% of the Prediabetes Market in 2025, equivalent to USD 119.24 million, and are projected to expand at an 8.12% CAGR during 2026–2032, reflecting their importance in structured patient management and preventive care services. By Geography: North American Screening Needs and Asia-Pacific Access Shape Demand Leading Region: North America North America accounted for 34% of the global Prediabetes Market, equivalent to USD 106.69 million in 2025, and is projected to expand at a CAGR of 5.47% during 2026–2032. Prediabetes affects a substantial population across the region, particularly in the United States, where rising obesity rates, sedentary lifestyles, and metabolic disorders are increasing the number of at-risk individuals. However, limited awareness, inconsistent screening practices, and low participation in structured diabetes prevention programs continue to restrict early identification and timely intervention. Fastest-Growing Region: Asia-Pacific Asia-Pacific accounted for 30% of the global Prediabetes Market in 2025, equivalent to USD 94.14 million, and is projected to record the fastest regional CAGR of 8.97% from 2026 to 2032. Adoption of prediabetes screening, diagnosis, and management is expanding across the region, supported by focus on diabetes prevention, routine checks, and early identification of elevated blood glucose. However, progress remains uneven: advanced screening pathways are more established in high-income countries, while developing healthcare systems build primary-care access and prevention programmes. Which Companies Are Shaping the Competitive Landscape of the Prediabetes Market? Eli Lilly and Company: SURMOUNT-1 Results Strengthen Its Position in Metabolic Risk Management Eli Lilly and Company has an important position in the pharmacological segment through its incretin-based therapies, particularly tirzepatide, marketed as Mounjaro and Zepbound in the United States. Its relevance to prediabetes is supported by the Phase III SURMOUNT-1 clinical trial, which evaluated adults with obesity or overweight, including 1,032 participants with prediabetes. At 176 weeks, only 1.3% of participants receiving tirzepatide developed type 2 diabetes, compared with 13.3% in the placebo group, representing a 94% reduction in relative risk. Participants receiving the 15 mg dose also achieved an average body-weight reduction of 22.9%. These findings strengthen Lilly's clinical position in obesity-associated metabolic risk management and create opportunities in preventive metabolic healthcare. However, tirzepatide's approved indications should not be interpreted as a universal indication for treating prediabetes. Novo Nordisk: STEP 10 Results Support Semaglutide in Obesity-Related Intervention Novo Nordisk is another important pharmaceutical participant through its GLP-1-based portfolio, particularly semaglutide. The company's Phase III STEP 10 trial specifically evaluated semaglutide 2.4 mg in adults with obesity and prediabetes. The study enrolled 207 participants across 30 clinical trial sites in five countries. After 52 weeks, 81% of participants receiving semaglutide achieved normoglycemia, compared with 14% receiving placebo. The semaglutide group also recorded an average body-weight reduction of 13.9%, compared with 2.7% in the placebo group. These clinical findings support Novo Nordisk's participation in the obesity-related metabolic intervention segment, particularly where weight management and glucose regulation overlap. Other Key Companies and Their Market Roles: Sanofi S.A.: Participates through its diabetes portfolio, including Toujeo and Soliqua, alongside patient education and diabetes-support initiatives such as Saath7, which supports approximately 100,000 patient enrolments annually in India. Abbott Laboratories: Contributes through FreeStyle Libre continuous glucose monitoring technology and its broader diagnostics portfolio. Abbott reported approximately 7 million FreeStyle Libre users worldwide and USD 6.8 billion in Diabetes Care revenue in 2024. Its CGM products primarily serve diabetes management rather than specifically indicated prediabetes treatment. Medtronic plc: Participates through MiniMed insulin pumps, continuous glucose monitoring integration, automated insulin delivery, and connected diabetes-management technologies. Its diabetes business generated approximately USD 2.18 billion in FY2026 revenue. Its principal commercial focus remains established diabetes management rather than routine prediabetes car Analyst Commentary: How Can Integrated Testing and Prevention Programs Strengthen Commercial Position? The prediabetes market presents a strong commercial opportunity in early risk identification and prevention-focused healthcare. Companies that integrate accessible diagnostic testing, structured weight-management programs, and clinically validated metabolic therapies can strengthen their position in the expanding preventive care landscape. Prediabetes Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 313.8 Million Revenue Forecast in 2032 USD 504.0 Million Overall Growth Rate CAGR of 7.0% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Disease Type, By Diagnosis, By Treatment, By Drug Class, By Monitoring, By End User, By Geography By Disease Type Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), Combined IFG and IGT By Diagnosis HbA1c Testing, Fasting Plasma Glucose (FPG) Testing, Oral Glucose Tolerance Test (OGTT) By Treatment Lifestyle Modification, Dietary Management, Pharmacological Management By Drug Class Biguanides (Metformin), GLP-1 Receptor Agonists, Other Glucose-Lowering Agents By Monitoring HbA1c Monitoring, Blood Glucose Monitoring Devices, Continuous Glucose Monitoring (CGM) Systems By End User Hospitals, Diabetes and Endocrinology Clinics, Diagnostic Laboratories By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Need for earlier identification of elevated blood glucose, expanded HbA1c and fasting glucose screening, participation in structured diabetes prevention programs, and repeat monitoring of at-risk individuals Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the market? A1. Growth is supported by a large undiagnosed prediabetes population, expanding HbA1c and glucose screening, preventive care programs, lifestyle interventions, and growing use of metabolic therapies. Q2. Which diagnostic method is gaining the strongest market position? A2. HbA1c testing leads the diagnosis segment with a 42% share in 2025 and is projected to grow at a CAGR of 8.00% during 2026–2032, supported by its role in screening and follow-up monitoring. Q3. Why are GLP-1 receptor agonists gaining importance in the industry? A3. GLP-1 receptor agonists are projected to record the fastest drug-class CAGR of 11.92% during 2026–2032, supported by their relevance in weight management and reducing progression risk among selected high-risk individuals. Q4. Which monitoring technology offers the strongest growth opportunity in the market? A4. Continuous glucose monitoring systems are projected to grow at a CAGR of 11.43% during 2026–2032. Their ability to track glucose patterns and support personalized lifestyle interventions is expanding their role in preventive metabolic care. Q5. Which end-user segment is expected to expand the fastest? A5. Diabetes and endocrinology clinics are projected to record the fastest end-user CAGR of 8.12% during 2026–2032, supported by specialized risk assessment, lifestyle guidance, and long-term glucose monitoring. Q6. Which region is expected to record the fastest growth in the market? A6. Asia-Pacific is projected to record the fastest regional CAGR of 8.97% during 2026–2032. Growth is supported by expanding screening, diabetes prevention initiatives, and improving primary-care access. Sources: U.S. CDC – Estimated That 115.2 Million U.S. Adults Aged 18 Years and Older Had Prediabetes in 2023, Supporting the Content’s Assessment of the Population Requiring Screening and Preventive Care CDC – National Diabetes Statistics Report: Prediabetes Prevalence U.S. CDC – Reported Age-Adjusted Prediabetes Awareness of 19.8% During 2021–2023, Highlighting the Gap Between Elevated Blood Glucose and Patient Awareness CDC – National Diabetes Statistics Report: Prediabetes Awareness Trends U.S. CDC – A Study of 1,338,509 Adults Aged 40–70 With Overweight or Obesity Found That 33.4% Received HbA1c or Fasting Plasma Glucose Testing Over Three Years; Testing Reached 74.3% When Other Glucose Measurements Were Included CDC – Blood Glucose Testing Among U.S. Adults With Overweight or Obesity, 2016–2019 U.S. National Institute of Diabetes and Digestive and Kidney Diseases – Identifies HbA1c, Fasting Plasma Glucose, and Oral Glucose Tolerance Testing as the Three Recommended Methods for Diagnosing Prediabetes NIDDK – Recommended Tests and Diagnostic Thresholds for Identifying Prediabetes U.S. National Institute of Diabetes and Digestive and Kidney Diseases – Reports That Intensive Lifestyle Intervention Reduced Type 2 Diabetes Incidence by 58% and Metformin by 31% Compared With Placebo Over Approximately Three Years in the Diabetes Prevention Program NIDDK – Diabetes Prevention Program: Lifestyle Intervention and Metformin Evidence Medicare – Covers a Structured Diabetes Prevention Program for Eligible Beneficiaries, Including 16 Core Sessions and Six Follow-Up Sessions, With No Patient Charge for Those Who Qualify Medicare – Diabetes Prevention Program Coverage, Eligibility, and Services Labcorp – Offers Hemoglobin A1c Test 001453 for Diagnosing Diabetes, Assessing Long-Term Glucose Control, and Identifying Patients at Increased Risk of Diabetes, Including Prediabetes Labcorp – Hemoglobin A1c Testing for Diabetes and Prediabetes Identification Quest Diagnostics – Offers a Hemoglobin A1c Test to Assess Prediabetes or Diabetes Risk and Support Follow-Up Blood Glucose Assessment Quest Diagnostics – Hemoglobin A1c Test and Prediabetes Risk Assessment Omada Health – Provides Prevention and Weight Health Programs Combining Health Coaching, Digital Support, and Connected Scales, With Coaches Trained in Lifestyle Approaches Used by CDC-Recognized Diabetes Prevention Programs Omada Health – Prevention Program Services, Coaching, and Connected Monitoring Lark Health – Offers a Fully CDC-Recognized Digital Diabetes Prevention Program Focused on Sustainable Lifestyle Changes for Members at Risk of Developing Type 2 Diabetes Lark Health – Digital Diabetes Prevention Program Noom – Offers a CDC-Recognized Diabetes Prevention Program Focused on Behavior Change and Sustainable Lifestyle Habits to Reduce Diabetes Risk Noom – Diabetes Prevention Program and Lifestyle Support Eli Lilly and Company – Reported SURMOUNT-1 Results on November 13, 2024, Showing a 94% Reduction in Progression to Type 2 Diabetes Over 176 Weeks Under the Efficacy Estimand, With Average Weight Reduction of 22.9% at the 15 mg Tirzepatide Dose Lilly – Tirzepatide Three-Year Results in Adults With Prediabetes and Obesity or Overweight Novo Nordisk – Its STEP 10 Study Summary Reports That 81.1% of Semaglutide-Treated Participants Achieved Normal Glucose Levels at 52 Weeks Versus 14.1% With Placebo, With Weight Reductions of 13.9% and 2.7%, Respectively Novo Nordisk – STEP 10: Semaglutide Results in Adults With Obesity and Prediabetes Abbott – Reported Approximately Seven Million FreeStyle Libre Users Worldwide and USD 6.8 Billion in Diabetes Care Revenue for 2024; These Figures Describe Its Broader Diabetes Business Rather Than Prediabetes-Specific Revenue Abbott – FreeStyle Libre User Reach and Diabetes Care Commercial Performance U.S. FDA – Cleared Dexcom Stelo on March 5, 2024, as the First Over-the-Counter Continuous Glucose Monitor for Adults Not Using Insulin, Including People Without Diabetes Seeking to Understand Glucose Responses to Diet and Exercise FDA – First Over-the-Counter Continuous Glucose Monitor Clearance Sanofi – Reports Approximately 100,000 Annual Patient Enrolments in Its Saath7 Support Program in India; This Supports Its Diabetes Education Role, Rather Than Demonstrating Prediabetes-Specific Treatment Activity Sanofi – Saath7 Diabetes Patient Support Program and Annual Enrolment Table of Contents – Global Prediabetes Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Investment Opportunities in the Prediabetes Market Key Developments and Innovations Strategic Partnerships and Collaborations High-Growth Segments for Investment Opportunities in HbA1c Testing, Fasting Plasma Glucose Testing, Oral Glucose Tolerance Testing, and Early Screening Investment Opportunities in Structured Lifestyle Modification and Dietary Management Programs Opportunities in Metformin, GLP-1 Receptor Agonists, and Other Glucose-Lowering Agents Growth Opportunities in HbA1c Monitoring, Blood Glucose Monitoring Devices, and Continuous Glucose Monitoring Systems Digital Diabetes Prevention Platforms and Remote Patient Monitoring Opportunities Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Prediabetes and Its Role as an Intermediate Metabolic Condition Strategic Importance of Early Blood Glucose Screening, HbA1c Testing, and Diabetes Risk Assessment Role of Preventive Medication, Lifestyle Modification, Dietary Management, and Follow-Up Monitoring Importance of Structured Diabetes Prevention Programs and Digital Healthcare Platforms Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Forecasting Framework (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Healthcare Access, Screening Awareness, and Preventive Care Policies Role of Early Blood Glucose Screening and HbA1c Testing in Prediabetes Identification Impact of Lifestyle Modification, Dietary Management, and Weight Management Programs Role of Metformin and GLP-1 Receptor Agonists in Selected High-Risk Patients Importance of Regular HbA1c Monitoring and Blood Glucose Assessment Digital Diabetes Prevention Platforms and Patient Engagement Trends Challenges Related to Low Prediabetes Awareness, Screening Gaps, and Patient Retention Global Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type: Impaired Fasting Glucose (IFG) Impaired Glucose Tolerance (IGT) Combined IFG and IGT Market Analysis by Diagnosis: HbA1c Testing Fasting Plasma Glucose (FPG) Testing Oral Glucose Tolerance Test (OGTT) Market Analysis by Treatment: Lifestyle Modification Dietary Management Pharmacological Management Market Analysis by Drug Class: Biguanides (Metformin) GLP-1 Receptor Agonists Other Glucose-Lowering Agents Market Analysis by Monitoring: HbA1c Monitoring Blood Glucose Monitoring Devices Continuous Glucose Monitoring (CGM) Systems Market Analysis by End User: Hospitals Diabetes and Endocrinology Clinics Diagnostic Laboratories Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Country-Level Breakdown: United States Canada Mexico Europe Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Prediabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Eli Lilly and Company Novo Nordisk A/S Sanofi S.A. Abbott Laboratories Medtronic plc Labcorp Quest Diagnostics Omada Health Lark Health Noom, Inc. Roche Diagnostics Siemens Healthineers AG Dexcom, Inc. Teladoc Health, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Diagnostic Testing, Preventive Medication, Lifestyle Programs, Digital Platforms, and Monitoring Technologies HbA1c and Blood Glucose Testing Portfolio Positioning Metformin and GLP-1 Receptor Agonist Market Positioning Digital Diabetes Prevention Program Capabilities Continuous Glucose Monitoring and Connected Healthcare Technology Strategies Patient Enrollment, Retention, and Preventive Care Service Strategies Healthcare Provider Partnerships and Regional Market Presence Appendix Abbreviations and Terminologies Used in the Report References and Sources Market Definitions and Segmentation Scope Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) List of Tables Market Size by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Prediabetes Market Participants Diagnostic Testing and Monitoring Technology Analysis Preventive Treatment and Drug Class Analysis Digital Diabetes Prevention and Lifestyle Intervention Program Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Disease Type, Diagnosis, Treatment, Drug Class, Monitoring, and End User (2025 vs. 2032) Global Prediabetes Market Ecosystem and Value Chain Analysis Prediabetes Screening, Diagnosis, and Preventive Care Pathway Digital Diabetes Prevention and Continuous Glucose Monitoring Adoption Trends